Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $1,523 | 3 | 51.8% |
| Food and Beverage | $812.38 | 13 | 27.6% |
| Unspecified | $607.05 | 2 | 20.6% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $1,605 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $754.89 | 4 | $0 (2024) |
| SOBI, INC | $582.85 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,061 | 11 | Adaptive Biotechnologies Corporation ($1,605) |
| 2023 | $691.30 | 5 | Novartis Pharmaceuticals Corporation ($431.05) |
| 2022 | $190.25 | 2 | Novartis Pharmaceuticals Corporation ($190.25) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $133.59 | General |
| Category: Oncology | ||||||
| 12/08/2024 | SOBI, INC | GAMIFANT (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: HEMATOLOGY | ||||||
| 10/03/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $612.07 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $611.75 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $299.43 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $26.20 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $14.90 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $29.75 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $10.84 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | SOBI, INC | GAMIFANT (Drug) | Food and Beverage | In-kind items and services | $72.48 | General |
| Category: HEMATOLOGY | ||||||
| 02/23/2024 | SOBI, INC | GAMIFANT (Drug) | Food and Beverage | In-kind items and services | $100.12 | General |
| Category: HEMATOLOGY | ||||||
| 12/12/2023 | SOBI, INC | Gamifant (Drug) | Food and Beverage | In-kind items and services | $116.28 | General |
| Category: HEMATOLOGY | ||||||
| 11/21/2023 | SOBI, INC | Gamifant (Drug) | Food and Beverage | In-kind items and services | $63.70 | General |
| Category: HEMATOLOGY | ||||||
| 09/21/2023 | SOBI, INC | Gamifant (Drug) | Food and Beverage | In-kind items and services | $75.87 | General |
| Category: HEMATOLOGY | ||||||
| 07/12/2023 | SOBI, INC | Gamifant (Drug) | Food and Beverage | In-kind items and services | $4.40 | General |
| Category: HEMATOLOGY | ||||||
| 02/17/2023 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | — | Cash or cash equivalent | $431.05 | Research |
| Study: CTL019B2401 • Category: Oncology | ||||||
| 09/30/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | KYMRIAH (Biological) | — | In-kind items and services | $176.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 02/01/2022 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CTL019B2401 | Novartis Pharmaceuticals Corporation | $431.05 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $176.00 | 1 |
About Dr. Kevin Mcnerney, MD
Dr. Kevin Mcnerney, MD is a Pediatric Hematology-Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2014. The National Provider Identifier (NPI) number assigned to this provider is 1922419456.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Mcnerney, MD has received a total of $2,943 in payments from pharmaceutical and medical device companies, with $2,061 received in 2024. These payments were reported across 18 transactions from 3 companies. The most common payment nature is "Travel and Lodging" ($1,523).
Practice Information
- Specialty Pediatric Hematology-Oncology
- Other Specialties Pediatric Hematology-Oncology, Student in an Organized Health Care Education/Training Program
- Location Chicago, IL
- Active Since 05/19/2014
- Last Updated 10/15/2024
- Taxonomy Code 2080P0207X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1922419456
Products in Payments
- clonoSEQ (Device) $1,605
- KYMRIAH (Drug) $564.64
- GAMIFANT (Drug) $322.60
- Gamifant (Drug) $260.25
- KYMRIAH (Biological) $190.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Chicago
Alexis Thompson, Md, MD
Pediatric Hematology-Oncology — Payments: $1.6M
James Labelle
Pediatric Hematology-Oncology — Payments: $249,251
Sherif Badawy, Md, MD
Pediatric Hematology-Oncology — Payments: $207,866
Dr. Loretta Li, M.d, M.D
Pediatric Hematology-Oncology — Payments: $187,559
Susan Cohn
Pediatric Hematology-Oncology — Payments: $125,685
Leonard Valentino, M.d, M.D
Pediatric Hematology-Oncology — Payments: $117,453